Zimmer Biomet’s ROSA knee robot has been used in 350,000 cases since it launched, and it is the No. 2 player in the U.S., CEO Ivan Tornos said in a May 5 earnings call.
Now the company is eyeing the next big developments in the flagship robot. In April, Zimmer Biomet submitted 510(k) materials to the FDA for ROSA Knee V15, something Mr. Tornos said he hopes will be “a dramatic transformation of ROSA in itself.”
“The value proposition of ROSA Knee V15 is going to enhance surgical accuracy and reproducibility by improving soft tissue laxity, a different user experience,” Mr. Tornos said, as transcribed by Seeking Alpha. “The platform has the ability of doing a kinematic knee. It has a new auto balance procedure, it’s faster, it’s simpler, it’s streamlined. So we believe there’s going to be an improvement on the current version of ROSA.”
Zimmer Biomet also plans to seek clearance for a CT imaging platform for ROSA, Mr. Tornos said.
